The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
Despite some progress in transparency related to the process for Section 1115 Medicaid waivers, the Centers for Medicare…
Chairperson's File
During Mental Health Month, let’s all remember that caring for the whole person improves health and saves lives.
Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Headline
A study released last week by Rand on prices paid by private health plans to hospitals “relied on severely limited data and questionable assumptions to draw…
Perspective
When the many vulnerable members of society need care, they often turn to their local hospital or health system.